ClinicalTrials.gg
CompletedNCT01074463Updated Apr 30, 2010Results posted

Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions

A Phase 1 interventional study of Pramipexole Dihydrochloride and Pramipexole Dihydrochloride in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-04-30.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The object of this study was to compare the relative bioavailability (rate and extent of absorption) of Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc. with that of Mirapex® Tablets 0.25 mg distributed by Boehringer Ingelheim Pharmaceuticals, Inc. following a single oral dose in healthy adults under non-fasting conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All volunteers selected for this study will be healthy men and women 18 to 45 years of age, inclusive.
  • The weight range will not exceed + 20% for height and body frame as per "Desirable Weights for Adults - 1983 Metropolitan Height and Weight Table"
  • Each volunteer will complete the screening process within 28 days prior to Period 1 dosing.
  • Consent documents for both the screening evaluation and antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.
  • If female: and of child bearing potential is practicing an acceptable method of for the duration of the study as judged by the investigator(s), is for at least 1 year, or is surgically sterile.

Exclusion criteria

Exclusion Criteria:

  • Volunteers with a recent history of drug or alcohol addiction or abuse.
  • Volunteers with the presence of a disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigator).
  • Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
  • Volunteers demonstrating a reactive screen for surface antigen, antibody, or antibody.
  • Volunteers demonstrating a positive drug abuse screen when screened for this study.
  • Female volunteers demonstrating a positive pregnancy screen.
  • Female volunteers who are currently breastfeeding.
  • Volunteers with a history of allergic response(s) to pramipexole or related drugs.
  • Volunteers with a history of clinically significant allergies including drug allergies.
  • Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
  • Volunteers who currently use tobacco products.
  • Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.
  • Volunteers who report donating greater than 150 mL of blood within 28 days prior to Period I dosing. All subjects will be advised not to donate blood for 4 weeks after completing the study.
  • Volunteers who have donated plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for 4 weeks after completing the study.
  • Volunteers who report receiving any drug within 28 days prior to Period I dosing.
  • Volunteer who report taking any systemic prescription medication in the 14 days prior to Period I dosing. Diltiazem (Cardizem®), triamterene (Dyrenium®), verapamil (Calan®, Covera-HS®), quinidine, and quinine are prohibited throughout the entire study.
  • Volunteers using OTC medication 7 days prior to dosing including vitamins, cough and cold preparations. Cimetidine (Tagamet®), ranitidine (Zantac®), probenecid (Pro-Bionate®), and any OTC antihistamine products (such as diphenhydramine, chlorpheniramine) are absolutely prohibited throughout the entire study.
  • Volunteers who consume food containing poppy seeds in the 48 hours before dosing of each period.
  • Volunteers who consume grapefruit or related products 14 days prior to Period I dosing.
  • Female volunteers who report the use of oral or injectable contraceptives.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    Pramipexole Dihydrochloride 0.25 mg Tablets

    Drug: Pramipexole Dihydrochloride

  • Active comparator
    2

    Mirapex® 0.25 mg Tablets

    Drug: Pramipexole Dihydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

    Bioequivalence based on Cmax.

    Time frame: Blood samples collected over a 48 hour period.

  2. AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Bioequivalence based on AUC0-t.

    Time frame: Blood samples collected over a 48 hour period.

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

    Bioequivalence based on AUC0-inf.

    Time frame: Blood samples collected over a 48 hour period.

07

Results

Posted Apr 30, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneTest (Pramipexole Dihydrochloride) FirstReference (Mirapex®) First
Started1212
Completed1212
Not completed00
Washout of 7 Days
Participant flow — Washout of 7 Days
MilestoneTest (Pramipexole Dihydrochloride) FirstReference (Mirapex®) First
Started1212
Completed1212
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneTest (Pramipexole Dihydrochloride) FirstReference (Mirapex®) First
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryCmax (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Cmax.

Time frame:
Blood samples collected over a 48 hour period.
Reported as:
Mean · ng/mL
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
ng/mLTest (Pramipexole Dihydrochloride)Reference (Mirapex®)
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)0.61 ± 0.220.54 ± 0.10
Statistical analysis
  • Test (Pramipexole Dihydrochloride) vs Reference (Mirapex®) · Ratio of the t/r geometric mean x 100: 109.18 · 90% CI 99.25 to 120.12Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t.

Time frame:
Blood samples collected over a 48 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
ng*h/mLTest (Pramipexole Dihydrochloride)Reference (Mirapex®)
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)5.86 ± 1.185.68 ± 1.36
Statistical analysis
  • Test (Pramipexole Dihydrochloride) vs Reference (Mirapex®) · Ratio of the t/r geometric mean x 100: 104.06 · 90% CI 98.73 to 109.68Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf.

Time frame:
Blood samples collected over a 48 hour period.
Reported as:
Mean · ng*h/mL
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
ng*h/mLTest (Pramipexole Dihydrochloride)Reference (Mirapex®)
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)6.27 ± 1.216.17 ± 1.40
Statistical analysis
  • Test (Pramipexole Dihydrochloride) vs Reference (Mirapex®) · Ratio of the t/r geometric mean x 100: 102.34 · 90% CI 97.78 to 107.11Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.

Adverse events

Collected over Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test (Pramipexole Dihydrochloride) First—0/24 (0%)2/24 (8.3%)
Reference (Mirapex®) First—0/24 (0%)4/24 (16.7%)
Most frequent other events
Most frequent other events
EventTest (Pramipexole Dihydrochloride) FirstReference (Mirapex®) First
DizzinessGeneral disorders2/240/24
HeadacheGeneral disorders0/242/24
NauseaGeneral disorders0/242/24
NervousnessGeneral disorders2/240/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Test (Pramipexole Dihydrochloride) FirstReference (Mirapex®) FirstTotal
<=18 years000
Between 18 and 65 years121224
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Test (Pramipexole Dihydrochloride) FirstReference (Mirapex®) FirstTotal
Female5712
Male7512
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Test (Pramipexole Dihydrochloride) FirstReference (Mirapex®) FirstTotal
Caucasian101222
Black101
Native American101
Region of Enrollment
Region of Enrollment(participants)Test (Pramipexole Dihydrochloride) FirstReference (Mirapex®) FirstTotal
United States121224
08

Study locations

1 site
  • PRACS Institute, Ltd.
    Fargo, North Dakota 58104, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Mar 2005 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2010
First posted
Feb 24, 2010
Start
Feb 2005
Primary completionActual
Mar 2005
CompletionActual
Mar 2005
Results first posted
Apr 30, 2010
Last update
Apr 30, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01074463
First posted
Feb 24, 2010
Start date
Feb 2005
Primary completion
Mar 2005
Completion
Mar 2005
Results posted
Apr 30, 2010
Last update
Apr 30, 2010

Study contacts

James D Carlson, Pharm. D
principal investigator · PRACS Institute, Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion